Tvardi Therapeutics, Inc. (TVRD) Upgraded to Outperform at Raymond James

Market Context

Tvardi Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.65 with a market capitalization of $42.1M. The stock has declined 86.2% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Raymond James's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Tvardi Therapeutics, Inc.

Among the 10 most recent ratings: 6 Buy, 3 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jul 08, 2026	Raymond James	Outperform	N/A
Jul 07, 2026	BTIG	Buy	N/A
Jun 08, 2026	HC Wainwright & Co.	Buy	N/A
Apr 20, 2026	Barclays	Underweight	N/A
Apr 01, 2026	BTIG	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TVRD Stock Page